重症肌无力：不断演变的治疗格局。
Myasthenia gravis: The evolving therapeutic landscape.
作者信息
Wolfe Gil I, Hanson Jonathan E, Silvestri Nicholas J
机构信息
From the Dept. of Neurology, Jacobs School of Medicine and Biomedical Sciences, Univ. at Buffalo, State University of New York, Buffalo, NY, USA.
出版信息
eNeurologicalSci. 2024 Nov 19;37:100541. doi: 10.1016/j.ensci.2024.100541. eCollection 2024 Dec.
Abstract
Pharmacological options in the management of generalized myasthenia gravis (gMG) have expanded rapidly in the last 7 years. There are now several complement inhibitors and neonatal Fc receptor antagonists on the market in many countries for patient management, following the successful completion of Phase 3 studies. In open-label extensions, these agents have proven to be effective over the longer term extending several years, with benefits such as reduction of corticosteroid requirements being observed. In the communication below, we will briefly summarize recent pharmacologic advancements in the management of gMG and outline how these agents are currently being used and may be used in the future.
摘要
在过去7年中，全身型重症肌无力（gMG）的药物治疗选择迅速增加。在3期研究成功完成后，目前许多国家市场上有几种补体抑制剂和新生儿Fc受体拮抗剂用于患者管理。在开放标签扩展研究中，这些药物已被证明在长达数年的长期治疗中有效，观察到诸如减少皮质类固醇需求等益处。在以下交流中，我们将简要总结gMG治疗方面的近期药物进展，并概述这些药物目前的使用方式以及未来可能的使用方式。
相似文献
1
Myasthenia gravis: The evolving therapeutic landscape.重症肌无力：不断演变的治疗格局。
eNeurologicalSci. 2024 Nov 19;37:100541. doi: 10.1016/j.ensci.2024.100541. eCollection 2024 Dec.
2
Rozanolixizumab in generalized myasthenia gravis: Pooled analysis of the Phase 3 MycarinG study and two open-label extensions.罗扎奴利昔单抗治疗全身型重症肌无力：3期MycarinG研究及两项开放标签扩展研究的汇总分析
J Neuromuscul Dis. 2025 Mar;12(2):218-230. doi: 10.1177/22143602241305511. Epub 2025 Mar 4.
3
Long-term safety of cyclical rozanolixizumab in patients with generalized myasthenia gravis: Results from the Phase 3 MycarinG study and an open-label extension.环磷酰胺在全身型重症肌无力患者中的长期安全性：3期MycarinG研究及开放标签扩展研究的结果
J Neuromuscul Dis. 2025 Mar;12(2):231-243. doi: 10.1177/22143602241308181. Epub 2025 Mar 4.
4
Efgartigimod Alfa in Generalised Myasthenia Gravis: A Profile of Its Use.依氟鸟氨酸治疗全身性重症肌无力：应用简介。
CNS Drugs. 2023 May;37(5):467-473. doi: 10.1007/s40263-023-01000-z. Epub 2023 Mar 31.
5
Assessing the symptom control provided by ravulizumab or efgartigimod in myasthenia gravis: an evaluation of the patient experience of two different treatment approaches.评估ravulizumab或efgartigimod对重症肌无力症状的控制：两种不同治疗方法的患者体验评估
Curr Med Res Opin. 2025 May;41(5):817-827. doi: 10.1080/03007995.2025.2497906. Epub 2025 May 24.
6
Patterns and predictors of therapeutic response to efgartigimod in acetylcholine receptor-antibody generalized myasthenia gravis subtypes.乙酰胆碱受体抗体阳性全身型重症肌无力各亚型中艾加莫德治疗反应的模式及预测因素
Ther Adv Neurol Disord. 2025 Feb 18;18:17562864251319656. doi: 10.1177/17562864251319656. eCollection 2025.
7
Eculizumab in Adolescent Patients With Refractory Generalized Myasthenia Gravis: A Phase 3, Open-Label, Multicenter Study.依库珠单抗治疗青少年难治性全身性重症肌无力患者的 3 期、开放标签、多中心研究。
Pediatr Neurol. 2024 Jul;156:198-207. doi: 10.1016/j.pediatrneurol.2024.04.020. Epub 2024 Apr 26.
8
Ravulizumab: A Review in Generalised Myasthenia Gravis.拉维珠单抗：在全身性重症肌无力中的应用评价。
Drugs. 2023 Jun;83(8):717-723. doi: 10.1007/s40265-023-01877-6. Epub 2023 May 11.
9
Overcoming therapeutic challenges: Successful management of a supposedly triple seronegative, refractory generalized myasthenia gravis patient with efgartigimod.克服治疗挑战：以依库珠单抗成功治疗一例疑似三重血清阴性、难治性全身性重症肌无力患者。
Eur J Neurol. 2024 Jul;31(7):e16306. doi: 10.1111/ene.16306. Epub 2024 May 8.
10
Long-Term Efficacy and Safety of Ravulizumab in Adults With Anti-Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis: Final Results From the Phase 3 CHAMPION MG Open-Label Extension.ravulizumab治疗抗乙酰胆碱受体抗体阳性全身型重症肌无力成人患者的长期疗效和安全性：3期CHAMPION MG开放标签扩展研究的最终结果
Eur J Neurol. 2025 Apr;32(4):e70158. doi: 10.1111/ene.70158.
引用本文的文献
1
Mesenchymal stromal cells conditioned by peripheral blood mononuclear cells exert enhanced immunomodulation capacities and alleviate a model of Myasthenia Gravis.经外周血单个核细胞处理的间充质基质细胞具有增强的免疫调节能力，并可缓解重症肌无力模型。
Stem Cell Res Ther. 2025 Aug 8;16(1):437. doi: 10.1186/s13287-025-04534-9.
本文引用的文献
1
Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis.瑞昔珠单抗治疗全身性重症肌无力。
NEJM Evid. 2022 May;1(5):EVIDoa2100066. doi: 10.1056/EVIDoa2100066. Epub 2022 Apr 26.
2
Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis.艾加莫德（ADAPT+）的长期安全性、耐受性及疗效：一项针对全身型重症肌无力患者的3期开放标签扩展研究的中期结果
Front Neurol. 2024 Jan 17;14:1284444. doi: 10.3389/fneur.2023.1284444. eCollection 2023.
3
Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study.在全身性重症肌无力患者中zilucoplan 的安全性和疗效（RAISE）：一项随机、双盲、安慰剂对照、3 期研究。
Lancet Neurol. 2023 May;22(5):395-406. doi: 10.1016/S1474-4422(23)00080-7.
4
Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study.Rozanolixizumab 在全身性重症肌无力患者中的安全性和疗效（MycarinG）：一项随机、双盲、安慰剂对照、适应性 3 期研究。
Lancet Neurol. 2023 May;22(5):383-394. doi: 10.1016/S1474-4422(23)00077-7.
5
IgG regulation through FcRn blocking: A novel mechanism for the treatment of myasthenia gravis.通过 FcRn 阻断来调节 IgG：治疗重症肌无力的新机制。
J Neurol Sci. 2021 Nov 15;430:118074. doi: 10.1016/j.jns.2021.118074. Epub 2021 Sep 13.
6
Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial.依氟鸟氨酸苷单抗在全身性重症肌无力患者中的安全性、疗效和耐受性（ADAPT）：一项多中心、随机、安慰剂对照、3 期临床试验。
Lancet Neurol. 2021 Jul;20(7):526-536. doi: 10.1016/S1474-4422(21)00159-9.
7
Concomitant Immunosuppressive Therapy Use in Eculizumab-Treated Adults With Generalized Myasthenia Gravis During the REGAIN Open-Label Extension Study.在REGAIN开放标签扩展研究中，接受依库珠单抗治疗的成年全身型重症肌无力患者同时使用免疫抑制疗法的情况。
Front Neurol. 2020 Nov 24;11:556104. doi: 10.3389/fneur.2020.556104. eCollection 2020.
8
Long-term safety and efficacy of eculizumab in generalized myasthenia gravis.依库珠单抗治疗全身性重症肌无力的长期安全性和有效性。
Muscle Nerve. 2019 Jul;60(1):14-24. doi: 10.1002/mus.26447. Epub 2019 Mar 8.
9
Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.依库珠单抗治疗乙酰胆碱受体抗体阳性的难治性全身性重症肌无力（REGAIN）的安全性和有效性：一项 3 期、随机、双盲、安慰剂对照、多中心研究。
Lancet Neurol. 2017 Dec;16(12):976-986. doi: 10.1016/S1474-4422(17)30369-1. Epub 2017 Oct 20.
10
Myasthenia Gravis.重症肌无力
N Engl J Med. 2016 Dec 29;375(26):2570-2581. doi: 10.1056/NEJMra1602678.
Zotero 插件